BIIB Stock Price : Is It Time To Buy Or Fold

BIIB Stock Price

Editor: Vladimir Bajic | Tactical Investor

BIIB Stock Price: Time to Buy or Hold

Before we get to the article at hand you might find the following article to be of interest:

Nearly ten years after the housing crisis:

And banks are getting ready to offer what they call fewer doc loans, which is just a stepping stone to the no-doc loan.  As we stated before banks need to put money into the hands of the masses so they can fuel the next bubble. A bubble needs mass participation and banks thrive of bubbles. Every bubble and bust cycle is created and masterminded by banks.  Banks never lose, they just pretend to, because they know they will be bailed out. The Fed is a private institute run and owned by the banks, so they have nothing to worry about.

“Lite Doc.” That is what Quontic Bank, an FDIC-insured community lender in New York City is calling its product. It requires only verification of employment and two months worth of bank statements. For self-employed borrowers, it requires documentation of one year of profit and losses. The Lite Doc loans are five-year adjustable-rate mortgages with interest rates in the low- to mid-5 per cent range, according to the bank. Thirty-year fixed-rate loans, which when fully documented can offer rates in the high-3 per cent range, are not part of the offering. Housing déjà vu-Banks ready to drain the Masses again

BIIB Stock Price: Is it a Buy?

Well, let’s see what the other experts are stating before we investigate the stock.  Let’s start off with Barrons

Biogen has had a difficult 2019, and most of its trouble stems from the late-stage trial failure of its Alzheimer’s treatment. News that the drug didn’t work led to a plunge rarely seen by companies as large as Biogen, since a lot of analysts and investors were banking on its success. The stock has yet to recover, despite a better-than-expected earnings report, ongoing stock buybacks, and the company’s decision to add three new directors to its board.

What’s new. On Thursday, Piper Jaffray analyst Christopher Raymondreiterated an Overweight rating and $280 price target on Biogen, citing meetings with management that left him confident in the company’s abilities to navigate through this tough period.

Raymond admits, “It is the rare occasion that an analyst is anything but ‘incrementally positive after traveling with management.”

“It’s fashionable to hate on Biogen right now, but we think that’s a mistake,” he adds. Full Story

 

Share wise Views on BIIB Stock Price

The target price of Biogen is $278.00 and it is currently rated as BUY.

Biogen is rated as Hold by analysts and as Buy by the crowd. We are unable to calculate a valuation analysis for Biogen at this time. Compared to the current price of Biogen of $236.80 on the main market NASDAQ, the price of Biogen might rise by 17.40% according to the estimates of analysts and the crowd.

Biogen has dropped by -0.55% since the last trading day. The current price is $236.80. Full Story

Yahoo’s Views on BIIB Stock Price

Reputable billionaire investors such as Jim Simons, Cliff Asness and David Tepper generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won’t accept your savings unless you commit at least $5 million) by pinpointing winning small-cap stocks. There is little or no publicly-available information at all on some of these small companies, which makes it hard for an individual investor to pin down a winner within the small-cap space. However, hedge funds and other big asset managers can do the due diligence and analysis for you instead, thanks to their highly-skilled research teams and vast resources to conduct an appropriate evaluation process. Looking for potential winners within the small-cap galaxy of stocks? We believe following smart money is a good starting point.

Biogen Inc. (NASDAQ: BIIB) was in 49 hedge funds’ portfolios at the end of the first quarter of 2019. BIIB has experienced a decrease in hedge fund interest lately. There were 57 hedge funds in our database with BIIB holdings at the end of the previous quarter. Our calculations also showed that biib isn’t among the 30 most popular stocks among hedge funds. Full Story 

Tactical Investor Outlook on Biogen Stock Price

BIIB Stock July 2019

BIIB Stock has taken a beating and from a mass psychology perspective, the masses are not going to embrace it immediately. The crowd is famous for buying at the top and selling at the bottom, which means that investors with longer time horizons and extra money could put some capital into this stock now as the downside is limited.

Having said that the stock faces a strong zone of resistance in 255 ranges; it would need to close above this level to have any shot at challenging the 300 ranges.  In order to trade past this level, it would have to overcome another formidable zone of resistance that comes into play in the 306 ranges.  If it manages to close above 306 on a monthly level then it will be in a position to test the 354-360 ranges, with a possible overshoot to as high as 380.

Finally, while the stock is trading in the extremely oversold ranges, the overall momentum is negative and the trend is neutral, which suggests that it could trend sideways for an extended period before breaking out.   We feel that Abiomed, Inc. (ABMD)would make for a better play as the outlook over the next 6-9 is decidedly more bullish as of July 30, 2019

Other articles of interest

Feds Interest Rate stance equates to Rubbish-Economic recovery is illusory  (Dec 24)

Stock Market Bulls, Stock Market fools-Market Crash next or is this just an Illusion  (Dec 21)

Trump Effect Rally-Useless Dow Theory and Stock Market Crash  (Dec 17)

Gold fools-dollar bulls and the long-term outlook for both Markets (Dec 9)

Inflation the Silent Killer Tax that’s destroying Middle-Class America (Dec 5)

Dominant Stock Market Trends under President Trump (Nov 22)

Bears State Crude Oil Destined to Crash-Utter Rubbish (Nov 18)

50 Trillion in Cash illustrates Mass Anxiety-Dow Industrials will soar not Crash  (Nov 16)

Trump’s victory Does not Sink Global Markets Proving Experts are Jackasses (Nov 10)

Trump-The New Stock Market vix Factor (Nov 6)

Crude Oil Market-Higher prices or Market Crash (Oct 28)

American’s fear the Stock Market-Understanding Market Sentiment key to winning  (Oct 24)

Foreign banks Dump whopping 356 billion in US Debt  (Oct 20)

Corporate Americas Share buyback Binge only force Keeping Stock Market Bull Alive (Oct 13)

Stock Market Earnings Recession Nothing to Fear-Market Still Trending higher (Oct 7)

Fed Directly limiting Market Downside Action-Expect Stock Market rally not Crash (Oct 6)

Dow theory no longer relevant-Better Alternative exists (Sept 30)